Evidence map›Paper›PMID 35754255›Full record

ReviewCell proliferation2022

The PI3K/AKT signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: Mechanisms and therapeutic opportunities.

Xuegang He, Ying Li, Bo Deng, Aixin Lin, Guangzhi Zhang, Miao Ma, Yonggang Wang, Yong Yang, Xuewen Kang

Open access · goldAbstract readReview
In one paragraph

Review in Cell proliferation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 2 pooled it
37.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 2 syntheses or guidelines pooled it, 285 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Development of aBioactive materials · 2026
    Article

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xuegang HeDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.ORCID https://orcid.org/0000-0002-2956-4569
Ying LiMedical School of Yan'an University, Yan'an University, Yan'an, China.
Bo DengDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Aixin LinDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Guangzhi ZhangDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Miao MaDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Yonggang WangDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Yong YangDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Xuewen KangDepartment of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.ORCID https://orcid.org/0000-0002-5877-9198
China International Science and Technology Cooperation · CNLanzhou University Second Hospital · CNYan'an University · CN

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2020-MS20Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2021-QN-A19Cuiying Scientific Training Program for Undergraduates of Lanzhou University Second Hospital CYXZ2020-02
6 · The paper itself

Abstract

objectsTraumatic spinal cord injury (TSCI) causes neurological dysfunction below the injured segment of the spinal cord, which significantly impacts the quality of life in affected patients. The phosphoinositide 3kinase/serine-threonine kinase (PI3K/AKT) signaling pathway offers a potential therapeutic target for the inhibition of secondary TSCI. This review summarizes updates concerning the role of the PI3K/AKT pathway in TSCI. MATERIALS AND

methodsBy searching articles related to the TSCI field and the PI3K/AKT signaling pathway, we summarized the mechanisms of secondary TSCI and the PI3K/AKT signaling pathway; we also discuss current and potential future treatment methods for TSCI based on the PI3K/AKT signaling pathway.

resultsEarly apoptosis and autophagy after TSCI protect the body against injury; a prolonged inflammatory response leads to the accumulation of pro-inflammatory factors and excessive apoptosis, as well as excessive autophagy in the surrounding normal nerve cells, thus aggravating TSCI in the subacute stage of secondary injury. Initial glial scar formation in the subacute phase is a protective mechanism for TSCI, which limits the spread of damage and inflammation. However, mature scar tissue in the chronic phase hinders axon regeneration and prevents the recovery of nerve function. Activation of PI3K/AKT signaling pathway can inhibit the inflammatory response and apoptosis in the subacute phase after secondary TSCI; inhibiting this pathway in the chronic phase can reduce the formation of glial scar.

conclusionThe PI3K/AKT signaling pathway has an important role in the recovery of spinal cord function after secondary injury. Inducing the activation of PI3K/AKT signaling pathway in the subacute phase of secondary injury and inhibiting this pathway in the chronic phase may be one of the potential strategies for the treatment of TSCI.

Indexed as

Phosphatidylinositol 3-KinasesSpinal Cord InjuriesApoptosisAxonsGliosisHumansInflammationNerve RegenerationPhosphatidylinositolsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktQuality of LifeSignal TransductionPhosphatidylinositol 3-KinasesPhosphatidylinositolsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID35754255
PMCPMC9436900
OpenAlexW4283581707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.